Image 2021 10 06 T10 49 00

Insights

Back to Insights
Blog Img

Cell and Gene Therapy, the Next Big Thing?

​It is not the first time there has been excitement around the untapped potential of Cell and Gene Therapy, but this time it is back and greater than before.

Being a head-hunter in the Pharmaceutical and Life Science industry gives me a unique position within the Cell and Gene Therapy market, enabling me to see the whole industry from above, changes companies are making, patterns forming, and the excitement around the ‘next big thing’.

It is not the first time there has been excitement around the untapped potential of Cell and Gene Therapy, but this time it is back and greater than before. Of course, safety is still a concern, but investigators are gaining ground and the recurring theme is that a string of cancer cures are sure to be on the way.

Cell and Gene Therapy is an upcoming wave of therapeutic innovation, although the technology for manufacturing these therapies is still at an early stage, meaning that the market is continuously adding new players to its niche. As it stands, there have been over 1000 clinical trials performed, each trial bringing the field even closer to its breakthrough moment.

The premium market intelligence report published by BIS Research titled “Global Cell and Gene Therapy Market” highlights that the market is projected to reach $25.00 billion by the end of 2027. The study also highlights that the market is set to witness a CAGR of 33.82% during 2021-2027. The growth is attributed to increasing incidences of cancer and other chronic diseases, and the increasing number of clinical trials, among others.

The number of academic and start-up biotech’s starting a journey within Cell and Gene Therapy has skyrocketed over the last few years and according to the Alliance for Regenerative Medicine, there are currently 1,220 ongoing clinical trials in this space, 152 of which are at phase III. Despite the global pandemic, investment in this area is also at a record high around the world, with the equivalent of €15.7B invested in 2020, a figure double that of 2019.

With this continued investment and research, I believe we are about to see a vast change in the way our industry works, with more and more clients of ours also starting to believe this is the next big thing. I, for one, am extremely excited to see this field reach its full potential, ultimately resulting in cancer related deaths witnessing a monumental decrease.

At Mantell Associates, we are currently partnered with a number of Cell and Gene Therapy organisations across Europe and the US. Please reach out to the team on +44 (0)20 3778 0990 if you want to be a part of something special and have a positive impact on millions across the globe.